不同剂量辛伐他汀治疗高血压合并高脂血症患者的疗效以及安全性的Meta分析

Efficacy and safety of simvastatin at different doses in patients with hypertension and hyperlipidemia:a Meta-analysis

目的系统评价不同剂量辛伐他汀治疗高血压合并高脂血症患者的疗效以及安全性。方法计算机检索CNKI、万方、CBM、VIP、PubMed、Cochrane Library数据库,搜集所有有关不同剂量辛伐他汀治疗高血压合并高脂血症的随机对照试验,检索时限均为建库至2019年11月。采用RevMan 5.3软件进行Meta分析。结果共纳入13篇文献,包括1966例患者。与20 mg/d比较,40 mg/d辛伐他汀显著改善收缩压、舒张压、总胆固醇、甘油三酯、高密度/低密度脂蛋白胆固醇和提高总有效率(P<0.01),但不良反应差异无统计学意义(P=0.58)。结论40 mg/d辛伐他汀治疗高血压合并高脂血症的疗效明显优于20 mg/d。

Objective To systematically evaluate the efficacy and safety of simvastatin at different doses in patients with hypertension and hyperlipidemia.Methods Randomized controlled trials(RCTs)of simvastatin at different doses for treating hypertension and hyperlipidemia were electronically retrieved from CNKI,WanFang,CBM,VIP,PubMed,and Cochrane Library databases until November 2019.Meta analysis was performed using RevMan 5.3 software.Results Thirteen articles were chosen,including 1966 cases.Compared with 20 mg/d simvastatin group,systolic/diastolic blood pressure,total cholesterol,triglycerides,and high/low-density lipoprotein cholesterol were lower,while total effective rate were higher in 40 mg/d simvastatin group(P<0.01).Adverse reactions were comparable between two groups(P=0.58).Conclusion The clinical efficacy of 40 mg/d simvastatin is superior to that of 20 mg/d simvastatin in patients with hypertension and hyperlipidemia.